GMS Ventures lifts Outlook Therapeutics (OTLK) stake in $5M share deal
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Outlook Therapeutics received a new investment from GMS Ventures & Investments, which bought 8,539,709 shares of common stock at $0.5855 per share in a registered direct offering for a total purchase price of about $5.0 million. Following this purchase, GMS Ventures reported indirect ownership of 22,092,068 common shares.
The filing also shows amendments to multiple warrant series held by GMS Ventures. Existing warrants with exercise prices of $2.26 and $1.40 per share were cancelled and replaced with new warrants covering the same share amounts at a reduced exercise price of $0.5855 per share, with expirations in 2030. The transactions are reported as cancellations of old warrants and acquisitions of new ones rather than exercises.
All securities are held of record by GMS Ventures. Ghiath M. Sukhtian controls GMS Ventures and may be deemed to share voting and investment power, but the reporting persons disclaim beneficial ownership except to the extent of any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 24,028,279 shares ($5,000,000)
Net Buy
7 txns
Insider
Sukhtian Ghiath M., GMS Ventures & Investments
Role
null | null
Bought
24,028,279 shs ($5.00M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| H | Warrants (right to buy) | 3,458,571 | $0.00 | -- |
| Purchase | Warrants (right to buy) | 3,458,571 | $0.00 | -- |
| H | Warrants (right to buy) | 3,458,571 | $0.00 | -- |
| Purchase | Warrants (right to buy) | 3,458,571 | $0.00 | -- |
| H | Warrants (right to buy) | 8,571,428 | $0.00 | -- |
| Purchase | Warrants (right to buy) | 8,571,428 | $0.00 | -- |
| Purchase | Common Stock | 8,539,709 | $0.5855 | $5.00M |
Holdings After Transaction:
Warrants (right to buy) — 0 shares (Indirect, See footnote);
Common Stock — 22,092,068 shares (Indirect, See footnote)
Footnotes (1)
- On May 28, 2026, GMS Ventures and Investments ("GMS Ventures") entered into a securities purchase agreement with Outlook Therapeutics, Inc. (the "Issuer") pursuant to which the Issuer agreed to issue and sell 8,539,709 shares of the Issuer's common stock at $0.5855 per share in a registered direct offering for a total purchase price of approximately $5.0 million. These securities are held of record by GMS Ventures. Ghiath M. Sukhtian ("Ghiath Sukhtian"), a natural person, is the holder of a controlling interest in GMS Ventures. GMS Ventures has designated two representatives to serve on the Issuer's board of directors. Therefore, each of GMS Ventures and Ghiath Sukhtian may be deemed a director by deputization. By virtue of the relationships described above in Footnote 2, Ghiath Sukhtian may be deemed to have voting and investment power with respect to the securities held by GMS Ventures noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are the beneficial owners of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The transactions reported in Table II above involved the amendment of the outstanding Tranche A warrants issued on January 16, 2025 to reduce the exercise price from $2.26 per share to $0.5855 per share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new one. The transactions reported in Table II above involved the amendment of the outstanding Tranche B warrants issued on January 16, 2025 to reduce the exercise price from $2.26 per share to $0.5855 per share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new one. The transactions reported in Table II above involved the amendment of the outstanding warrants issued on May 27, 2025 to reduce the exercise price from $1.40 per share to $0.5855 per share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new one.
Key Figures
Common shares purchased: 8,539,709 shares
Purchase amount: $5.0 million
Purchase price: $0.5855 per share
+5 more
8 metrics
Common shares purchased
8,539,709 shares
Registered direct offering at $0.5855 per share
Purchase amount
$5.0 million
Approximate total price for 8,539,709 shares
Purchase price
$0.5855 per share
Registered direct common stock offering
Common shares after transaction
22,092,068 shares
Indirect holdings following share purchase
Repriced warrant exercise price (Tranche A/B)
$0.5855 per share
Reduced from $2.26 per share for certain warrants
Repriced warrant exercise price (May 27, 2025 issue)
$0.5855 per share
Reduced from $1.40 per share for certain warrants
Tranche A warrant shares affected
3,458,571 warrants
Amendment reducing exercise price to $0.5855
May 27, 2025 warrant shares affected
8,571,428 warrants
Amendment reducing exercise price to $0.5855
Key Terms
registered direct offering, Tranche A warrants, Tranche B warrants, Rule 13d-3, +2 more
6 terms
registered direct offering financial
"issue and sell 8,539,709 shares of the Issuer's common stock at $0.5855 per share in a registered direct offering for a total purchase price"
A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.
Tranche A warrants financial
"amendment of the outstanding Tranche A warrants issued on January 16, 2025 to reduce the exercise price from $2.26 per share to $0.5855 per share"
Tranche B warrants financial
"amendment of the outstanding Tranche B warrants issued on January 16, 2025 to reduce the exercise price from $2.26 per share to $0.5855 per share"
Rule 13d-3 regulatory
"may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934"
Rule 13d-3 defines who is treated as the beneficial owner of a company’s shares for U.S. securities disclosure rules — essentially anyone who has the power to vote or direct how shares are voted, or the power to buy or sell them, even if they don’t hold the certificates. For investors this matters because crossing certain ownership thresholds triggers public filing and disclosure obligations and signals potential control or influence, much like having the keys to a car implies you can drive it even if it’s registered to someone else.
Section 16 regulatory
"This report shall not be deemed an admission that any of the Reporting Persons are the beneficial owners of such securities for the purpose of Section 16 of the Exchange Act"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
beneficial ownership financial
"may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
FAQ
What did GMS Ventures buy in Outlook Therapeutics (OTLK)?
GMS Ventures bought 8,539,709 Outlook Therapeutics common shares at $0.5855 per share. This purchase was made through a registered direct offering for a total price of about $5.0 million, increasing GMS Ventures’ indirect equity position in the company.
What happened to the Outlook Therapeutics warrants held by GMS Ventures?
Several Outlook Therapeutics warrant series held by GMS Ventures were amended. Older warrants with higher exercise prices of $2.26 and $1.40 per share were cancelled and replaced with new warrants at a reduced $0.5855 exercise price, keeping the same share amounts and 2030 expirations.
Is the $5.0 million Outlook Therapeutics investment an open-market trade?
The $5.0 million investment was made via a securities purchase agreement in a registered direct offering, not ordinary open-market buying. Outlook Therapeutics agreed to issue and sell 8,539,709 new common shares to GMS Ventures at $0.5855 per share.
Were the Outlook Therapeutics warrant changes exercises or repricings?
The warrant changes were repricings, not exercises. Existing Tranche A, Tranche B, and May 27, 2025 warrants were amended by cancelling the old instruments and issuing new warrants with lower $0.5855 exercise prices, reported as cancellations and acquisitions in the filing.